Evidence map›Paper›PMID 39239150›Full record

ArticleBrain communications2024

Comparative analysis of neurofilaments and biomarkers of muscular damage in amyotrophic lateral sclerosis.

Maximilian Vidovic, Hanna Sophie Lapp, Constanze Weber, Lydia Plitzko, Michael Seifert, Petra Steinacker, Markus Otto, Andreas Hermann, René Günther

Abstract read
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maximilian VidovicDepartment of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307  Germany.ORCID https://orcid.org/0000-0003-1453-1681
Hanna Sophie LappDepartment of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307  Germany.
Constanze WeberDepartment of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307  Germany.
Lydia PlitzkoDepartment of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307  Germany.
Michael SeifertCarl Gustav Carus Faculty of Medicine, Institute for Medical Informatics and Biometry (IMB), Technische Universität Dresden, Dresden 01307, Germany.ORCID https://orcid.org/0000-0002-2844-053X
Petra SteinackerDepartment of Neurology, Martin-Luther-University of Halle-Wittenberg, Halle (Saale) 06120, Germany.
Markus OttoDepartment of Neurology, Martin-Luther-University of Halle-Wittenberg, Halle (Saale) 06120, Germany.
Andreas HermannTranslational Neurodegeneration Section 'Albrecht Kossel', Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock 18147, Germany.ORCID https://orcid.org/0000-0002-7364-7791
René GüntherDepartment of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden 01307  Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diagnosis of the fatal neurodegenerative disease amyotrophic lateral sclerosis is challenging. Neurofilaments, indicative of neuronal damage, along with creatine kinase, creatinine, myoglobin, and troponin T, representing muscular damage, have been identified as promising fluid biomarkers. This study aims to comprehensively assess and compare their diagnostic and prognostic potential in a 'real-world' cohort of patients with amyotrophic lateral sclerosis. About 77 patients with amyotrophic lateral sclerosis and its clinical variants, and 26 age- and sex-matched controls with various neuromuscular and neurodegenerative diseases, were retrospectively included in this monocentric, cross-sectional study. Neurofilaments in cerebrospinal fluid and biomarkers of muscular damage in serum were measured and correlated with demographic features, motor function, survival time, clinical phenotypes, and the extent of upper and lower motor neuron involvement. Neurofilament, myoglobin, and troponin T concentrations were higher in patients with amyotrophic lateral sclerosis compared to disease controls. Higher neurofilament levels correlated with lower motor function and faster disease progression rate, while higher creatine kinase and creatinine concentrations were linked to preserved motor function. In contrast, troponin T elevation indicated poorer fine and gross motor functions. Increased neurofilament levels were associated with shorter survival, whereas biomarkers of muscular damage lacked survival correlation. Neurofilament concentrations were higher in classical amyotrophic lateral sclerosis than in progressive muscular atrophy, while myoglobin and troponin T levels were elevated in progressive muscular atrophy compared to primary lateral sclerosis. Neurofilaments were predominantly linked to upper motor neuron involvement. Our findings confirmed the robust diagnostic and prognostic value of neurofilaments in amyotrophic lateral sclerosis. Elevated neurofilament concentrations were associated with higher disease severity, faster disease progression, shorter survival, and predominant upper motor neuron degeneration. Biomarkers of muscular damage were inferior in distinguishing amyotrophic lateral sclerosis from other neuromuscular and neurodegenerative diseases. However, they may serve as complementary biomarkers and support in discriminating clinical variants of amyotrophic lateral sclerosis.

Indexed as

ALSamyotrophic lateral sclerosisbiomarkersbiomarkers of muscular damageneurofilaments

Identifiers

PMID39239150
PMCPMC11375854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.